Dana Chitu

Dana Chitu is a Researcher at the Hematology department of Erasmus MC. Her research focuses on understanding treatment responses and clinical outcomes in hematological malignancies, particularly myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and Burkitt lymphoma. She investigates drug mechanisms, stem cell biology, and therapeutic combinations to improve patient outcomes.

• Research Interests: Lenalidomide mechanisms, leukemia stem cells, hypomethylating agents, FLT3 mutation effects, erythropoiesis-stimulating agents, and clinical trial design.
• Key Projects: HOVON89 trial on MDS treatment, AML non-intensive therapy studies, and phase 3 trials for Burkitt lymphoma regimens.

Her recent publications (2023–2025) analyze treatment efficacy, gene expression predictors, and clinical trial outcomes in hematology. Collaborations span European institutions, emphasizing translational research and multidisciplinary approaches.